Journal of Obesity & Metabolic Syndrome (Jun 2020)

Current Long-Term Pharmacotherapies for the Management of Obesity

  • Bo-Yeon Kim,
  • Seon Mee Kang,
  • Jee-Hyun Kang,
  • Kyoung Kon Kim,
  • Bomtaeck Kim,
  • Seung Jun Kim,
  • Yang-Hyun Kim,
  • Jung-Hwan Kim,
  • Jae Hyun Kim,
  • Ga Eun Nam,
  • Ji Yeon Park,
  • Jang Won Son,
  • Hye-Jung Shin,
  • Tae Jung Oh,
  • Hyug Lee,
  • Eon-Ju Jeon,
  • Sochung Chung,
  • Yong Hee Hong,
  • Chong Hwa Kim,
  • Committee of Clinical Practice Guidelines, Korean Society for the Study of Obesity (KSSO)

DOI
https://doi.org/10.7570/jomes20010
Journal volume & issue
Vol. 29, no. 2
pp. 99 – 109

Abstract

Read online

Obesity is a serious and growing worldwide health challenge associated with type 2 diabetes mellitus, cardiovascular disease, osteoarthritis, some cancers, sleep apnea, asthma, and nonalcoholic fatty liver. The Korean Society for the Study of Obesity recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients with a body mass index ≥25 kg/m². Long-term medications for obesity have traditionally fallen into two major categories: centrally acting anorexiant medications and peripherally acting medications, such as orlistat. In this paper, we provide an overview of the anti-obesity medications currently available for the long-term and individualized treatment of obesity.

Keywords